ArticleScientific reports2025
Insight into immunoregulatory and neuromodulatory capability of Bacteroides cellulosilyticus and Bacteroides xylanisolvens human gut microbiota isolates.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Gut Microbiota and Metabolites: Orchestrating Depression Pathogenesis Through the Microbiota-Gut-Brain Axis's Neural, Immune, and Metabolic Routes.Biomolecules · 2026Review
- Opinion: Gavage Administration of MXene as a Route-Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post-Transplantation Models with Bile Acid Modification.Advanced healthcare materials · 2026Article
- Detoxification of Ochratoxin A byFoods (Basel, Switzerland) · 2026Article
- Current Evidence from Animal Models on Molecular Changes Underlying Antidepressant Effects of Psychobiotics.Pharmaceutics · 2026Review
- Novel insights into gut microbiota alterations in major depressive disorder with suicidal ideation: a metagenomic analysis.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Alterations in the abundance of Bacteroides species are linked to the disruption of the intestinal epithelial barrier and chronic inflammation and has been increasingly recognized as a factor in the development of neurological and neuropsychiatric disorders. Nevertheless, the exact role of Bacteroides species in the gut-brain cross-talk is still largely unexplored. Here, we investigated the immunoregulatory and neuromodulatory potential of two poorly characterized Bacteroides species, including Bacteroides cellulosilyticus and Bacteroides xylanisolvens. The results revealed that both Bacteroides isolates reduced inflammation in Caco-2 intestinal epithelial cells by decreasing the level of IL-8 chemokine and transcription of NF-kB, the two key factors involved in gut inflammation development and barrier disruption. In addition, the Bacteroides strains in the co-culture of Caco-2 cells and phytohemagglutinin-stimulated PBMCs reduced the production of pro-inflammatory cytokines TNF-α and IL-1β, as well as Th1-polarizing IFN-γ cytokine. Finally, in Caenorhabditis elegans, Bacteroides strains differently modulated the expression of the genes implicated in GABA, serotonin and dopamine signaling and synaptic vesicles release pointed to the strain-specific effects of these isolates on neural function. Altogether, these in vitro results show that tested Bacteroides strains may exert anti-inflammatory and neuromodulatory effects, indicating their potential role in microbiota-gut-brain axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.